Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage

Journal of Virology

Volumn 72, Issue 9, 1998, Pages 6988-6996

  Cecilia, D ^a   Kewalramanl, Vineet N ^a   O'Leary, Jeanne ^b   Volsky, Barbara ^a   Nyambi, Phillipe ^a   Burda, Sherri ^a   Xu, Serena ^a,d   Littman, Dan R ^a,c   Zolla Pazner, Susan ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VIRUS RECEPTOR;

ARTICLE; GENETIC ENGINEERING; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

EID: 0031818178     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.9.6988-6996.1998     Document Type: Article

References (54)

1. Arendrup, M., A. Sonnerborg, B. Svennerholm, L. Akerblom, C. Nielsen, H. Clausen, S. Olofsson, J. O. Nielsen, and J. S. Hansen. 1993. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J. Gen. Virol. 74:855-863.
2. Armstrong, S. J., T. L. McInerney, L. McLain, B. Wahren, J. Hinkula, M. Levi, and N. J. Dimmock. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77:2931-2941.
3. Auewarakul, P., S. Louisirirotchanakul, R. Sutthent, T. Taechowisan, C. Kanoksinsombat, and C. Wasi. 1996. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env genetic subtype B and E viruses in Thailand. Viral Immunol. 9:175-185.
4. Back, N. K., L. Smit, E. Hogervorst, A. C. van Wijk, J. Goudsmit, and M. Tersmette. 1994. Development and evaluation of an HIV-1 transtection-neutralization assay. J. Acquired Immune Defic. Syndr. 7:531-538.
5. Bandres, J. C., Q. F. Wang, J. O'Leary, F. Baleaux, A. Amara, J. Hoxie, S. Zolla-Pazner, and M. K. Gorny. 1998. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J. Virol. 72:2500-2504.
6. Bastiani, L., S. Laal, S. Zolla-Pazner, and M. Kim. 1997. Host cell-dependent alterations in envelope components of HIV-1 virions. J. Virol. 71:3444-3450.
7. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. MacKay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930.
8. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
9. Candotti, D., M. Rosenheim, J. M. Huraux, and H. Agut. 1997. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates. J. Virol. Methods 64:81-93.
10. Chen, Y. H., and M. P. Dierich. 1996. Identification of a second site in HIV-1 gp41 mediating binding to cells. Immunol. Lett. 52:153-156.
11. Ciminale, V., B. K. Felber, M. Campbell, and G. N. Pavlakis. 1990. A bioassay for HIV-1 based on env-CD4 interaction. AIDS Res. Hum. Retroviruses 6:1281.
12. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, D. Lineberger, E. A. Emini, M. Ossorio, S. Koenig, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
13. Deng, H., D. Unutmaz, V. N. Kewalramani, and D. R. Littman. 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300.
14. D'Souza, M. P., D. Livnat, J. A. Bradac, S. H. Bridges, and The AIDS Clinical Trials Group Antibody Selection Working Group. 1997. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1056-1062.
15. Fortin, J., R. Cantin, G. Lamontagne, and M. Tremblay. 1997. Hostderived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 71:3588-3596.
16. Frank, I., H. Stoiber, S. Godar, H. Stockinger, F. Steindl, H. W. D. Katinger, and M. P. Dierich. 1996. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 10:1611-1620.
17. Gauduin, M., G. P. Allaway, P. J. Maddon, C. F. Barbas III, D. R. Burton, and R. A. Koup. 1996. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J. Virol. 70:2586-2592.
18. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
19. Gorny, M. K., T. C. VanCott, C. Hioe, Z. R. Israel, N. L. Michael, A. J. Conley, C. Williams, J. A. Kessler II, P. Chigurupati, S. Burda, and S. Zolla-Pazner. 1997. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and inter-clade cross-reactivity. J. Immunol. 159:5114-5122.
20. Gorny, M. K., J. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
21. He, J., Y. Chen, M. Farzan, H. Choe, A. Ohagen, S. Gartner, J. Busciglio, X. Yang, W. Hofmann, W. Newman, C. R. Mackay, J. Sodroski, and D. Gabuzda. 1997. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-649.
22. Hioe, C. E., S. Xu, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. 1997. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9:1281-1290.
23. Hogervorst, E., J. De Jong, A. Van Wijk, M. Bakker, M. Valk, P. Nara, and J. Goudsmit. 1995. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies. J. Virol. 69:6342-6351.
24. KewalRamani, V. N., B. Volsky, D. Kwon, W.-K. Xiang, J. Gao, D. Unutmaz, C. M. Hill, R. E. Sutton, and D. R. Littman. Unpublished data.
25. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
26. Laal, S., S. Burda, S. Sharpe, and S. Zolla-Pazner. 1993. A rapid, automated microplate assay for measuring neutralization of HIV-1. AIDS Res. Hum. Retroviruses 9:781-785.
27. LaCasse, R. A., K. E. Follis, T. Moudgil, M. Trahey, J. M. Binley, V. Planellas, S. Zolla-Pazner, and J. H. Nunberg. 1998. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J. Virol. 72:2491-2495.
28. Mascola, J. R., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke. 1994. Two antigenically distinct subtypes of HIV-1: viral genotype predicts neutralization immunotype. J. Infect. Dis. 169:48-54.
29. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke, for the NIAID AIDS Vaccine Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
30. McInerney, T. L., L. McLain, S. J. Armstrong, and N. J. Dimmock. 1997. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 233:313-326.
31. McKeating, J. A., J. Bennett, S. Zolla-Pazner, M. Schutten, S. Ashelford, A. L. Brown, and P. Balfe. 1993. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J. Virol. 67:5216-5225.
32. McLain, L., and N. J. Dimmock. 1994. Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75:1457-1460.
33. Means, R. E., T. Greenough, and R. C. Desrosiers. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:7895-7902.
34. Monteflori, D. C., R. G. Collman, T. R. Fouts, J. Y. Zhou, M. Bilska, J. A. Hoxie, J. P. Moore, and D. P. Bolognesi. 1998. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J. Virol. 72: 1886-1893.
35. Myers, G., B. Korber, B. Foley, R. F. Smith, K. Jeang, J. W. Mellors, and A. Wain-Hobson. 1996. Human retroviruses and AIDS. Theoretical Biology and Biophysics, Los Alamos National Laboratories, Los Alamos, N.M.
36. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. D. Walers, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 (IIIB) infection of chimpanzees. J. Virol. 64: 3779-3791.
37. Nyambi, P. N., L. Heyndrickx, W. Janssens, F. Daeyaert, P. Lewi, K. Fransen, B. Willems, S. Coppens, K. Vereecken, P. Piot, and G. van der Groen. Identification of specific amino acid motifs and biophenotypic properties among primary HIV-1 group M (subtype A-H) and O isolates belonging to different neutralization clusters. Submitted for publication.
38. Nyambi, P. N., J. Nkengasong, P. Lewi, K. Andries, W. Janssens, K. Fransen, L. Heyndrickx, P. Piot, and G. van der Groen. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235-6243.
39. Reitz, M. S., C. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff. 1988. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57-63.
40. Rizzuti, C. D., and J. G. Sodroski. 1997. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J. Virol. 71:4847-4851.
41. Roben, P., J. P. Moore, M. Thali, J. Sodroski, and C. F. Barbas III. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
42. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 1997. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 227:2005-2007.
43. Sawyer, L. W., M. T. Wrin, L. Crawford-Miksza, B. Potts, Y. We, P. A. Weber, R. D. Alfonso, and C. V. Hanson. 1994. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68:1342-1349.
44. Scarlatti, G., J. Albert, P. Rossi, V. Hodara, P. Biraghi, L. Muggiasca, and E. M. Fenyo. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168:207-210.
45. Trkola, A., T. Ketas, V. N. KewalRamani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.
46. Ugolini, S., I. Mondor, P. W. H. I. Parren, D. R. Burton, S. Tilley, P. J. Klasse, and Q. J. Sattentau. 1997. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J. Exp. Med. 186:1287-1298.
47. Uguccioni, M., C. R. Mackay, B. Ochensberger, P. Loetscher, S. Rhis, G. J. LaRosa, P. Rao, P. D. Ponath, M. Baggíolíní, and C. A. Dahinden. 1997. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J. Clin. Invest. 100:1137-1143.
48. VanCott, T. C., F. R. Bethkes, V. R. Polonis, M. G. Gorny, S. Zolla-Pazner, R. R. Redfleld, and D. L. Birx. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449-459.
49. Weber, J., E.-M. Fenyo, S. Beddows, P. Kaleebu, A. Bjorndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtype J. Virol. 70:7827-7832.
50. Zhang, L., T. He, K. Kuntsman, S. Wu, Y. Guo, A. U. Neumann, D. D. Ho, and S. M. Wolinsky. 1998. HIV-1 phenotype, co-receptor usage and disease progression, abstr. 281, p. 132. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
51. Zolla-Pazner, S. 1996. Mechanisms contributing to the neutralization of HIV-1. Immunol. Lett. 51:89-93.
52. Zolla-Pazner, S., C. Alving, R. Belshe, P. Berman, S. Burda, P. Chigurupati, M. L. Clements, A.-M. Duliege, J.-L. Excler, J. Kahn, M. J. McElrath, S. Sharpe, F. Sinangil, K. Steimer, M. C. Walker, N. Wassef, and S. Xu. 1997. Neutralization of a clade B primary isolate by sera from HIV-uninfected recipients of candidate AIDS vaccines. J. Infect. Dis. 175:764-774.
53. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, and M. Robert-Guroff. 1998. Induction of neutralizing antibodies in T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.
54. Zolla-Pazner, S., and S. Sharpe. 1995. A resting cell assay for improved detection of antibody-mediated neutralization of HIV-1 primary isolates. AIDS Res. Hum. Retroviruses 11:1449-1457.